Delve Health Provides the Technology Platform to Design Clinical Trials to Fit a Patient’s Lifestyle

Beyond Patient Engagement: Why Collaboration is Vital in Digital Healthcare and eClinical Solutions
In the era of digital healthcare, patient engagement has emerged as a key focus for healthcare providers. The ability to actively involve patients in their own health and care has shown promising results in improving outcomes and overall satisfaction. However, to truly transform the healthcare landscape, we must move beyond patient engagement and embrace collaboration as an essential element. At Delve Health, we feel collaboration is crucial in digital healthcare because of how it can revolutionize the way we deliver and receive health services. Empowering Patients Through Collaboration While patient engagement emphasizes active involvement, collaboration takes it a step further by establishing

SATURDAY, MAY 20—INTERNATIONAL CLINICAL TRIALS DAY 2023
As we celebrate International Clinical Trials Day in 2023, it is crucial to reflect on the significance of these trials in driving medical innovation, ensuring patient safety and shaping the future of healthcare. Delve Health is proud to be a part of the clinical research community and believe these are key reasons why clinical trials are more important than ever before. 1) Advancing Medical Knowledge: Clinical trials serve as the cornerstone for medical research, expanding our understanding of diseases, treatments and preventative measures. Though rigorous experimentation and observation, these trials generate invaluable data that drive evidence-based medicine. They contribute to

Delve Health Comments on FDA Draft Guidance on Decentralized Clinical Trials for Drugs and Biological Products
Our Review of the New FDA Draft Guidance Decentralized clinical trials (DCTs) have become increasingly popular in recent years due to their potential to increase patient access and reduce the burden of participating in clinical trials. In response to this trend, the US Food & Drug Administration (FDA) has issued new guidance on the use of DCTs for drugs, biological products and medical devices. The FDA defines DCTs as “clinical trials in which some or all aspects of the trial are conducted at a site or sites other than the sites where the patients are located, using technology to collect

Delve Health and cerascreen Announce a Partnership to Offer a “One-Stop Solution” Digital Healthcare App
FOR IMMEDIATE RELEASE: May 11, 2023 CONTACT:+1.952.200.6228media@delvehealth.com Minneapolis, MN – Delve Health, a virtual health and technology firm, and cerascreen®, an at-home health diagnostic testing company, are announcing an exciting partnership to expand access to digital healthcare solutions worldwide via smart and wearable devices (e.g., smart phones, tablets, wrist wearables, etc.). Delve Health provides a fully-customizable mobile and web-based platform that enables cerascreen consumers the opportunity to monitor and track their health data—supporting and empowering people to take a more active role in their own healthcare journey. “Our solution was designed to increase awareness and access to personalized healthcare. We

Digital Endpoints Have a Positive Effect on Clinical Trials
The use of technology has been increasing over the past few years, with devices such as wearables, biosensors, and other medical devices. One area where this has been particularly evident is the use of digital endpoints in clinical trials. Digital endpoints refer to data collected from digital sources, such as mobile apps and passively collected data via wearable devices; which are used to assess the efficacy of a treatment or intervention in a clinical trial. They allow more frequent, objective remote monitoring of patients during clinical studies. For example, a smartphone’s microphone might be used to diagnose or predict mild cognitive impairment